Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug giant Teva Pharmaceutical Industries (NYSE:TEVA) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Teva and see what CAPS investors are saying about the stock right now.

Teva facts

Headquarters (founded)

Petach Tikva, Israel (1901)

Market Cap

$32.6 billion



Trailing-12-Month Revenue

$20.3 billion


CEO Dr. Jeremy Levin (since 2010)
CFO Eyal Desheh (since 2008)

Return on Equity (average, past 3 years)



$2.9 billion / $14.7 billion

Dividend Yield




Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 1,769 members who have rated Teva believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, MMcCabeNMC, succinctly summed up the Teva bull case for our community:

Teva is a huge generic drug maker, with some outreach into the primary drug market. The company's balance sheet is strong, and the stock pays a reasonable dividend. With governments emphasizing cost controls for medical expense, Teva has a guaranteed market.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.